Canada GDP Growth Picks Up in 1Q But Pace Lags Expectations
By Robb M. Stewart
OTTAWA--Canada's economy picked up strongly in the early months of the year, though the pace was weaker than expected as a slower buildup in business inventory moderated a rise in household spending on services.
Gross domestic product, a broad measure of goods and services produced in the economy, rose 1.7% at an annualized rate in the first quarter to 2.366 trillion Canadian dollars, the equivalent of $1.729 trillion, Statistics Canada said Friday. Market expectations were for a 2.2% expansion for the period, just under the 2.8% growth the Bank of Canada has projected.
Canada's economy expanded by a downwardly revised 0.1% in the in the final three months of 2023 from the quarter before, markedly slower than the 1.0% growth previously estimated.
Industry-level data for March showed that the economy was essentially unchanged from the previous month after increasing 0.2% in February. That was in line with Statistics Canada's advance estimate for the month.
The data agency provided an early estimate for April that suggests that GDP rose 0.3% month-over-month.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 31, 2024 09:10 ET (13:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks